Saratov JOURNAL of Medical and Scientific Research
Home

Results of incorporating new anti-tuberculosis drugs into chemotherapy regimens in patients operated for multi-drug resistant pulmonary tuberculosis

Year: 2025, volume 21 Issue: №2 Pages: 187-193
Heading: Phthisiology Article type: Original article
Authors: Suleimanov S.Z., Sinitsyn M.V.
Organization: National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Moscow, Russia , Pirogov Russian National Research Medical University, Moscow, Russia
Summary:

Objective: to evaluate the outcomes of comprehensive treatment in patients who underwent surgery for pulmonary tuberculosis with multidrug resistance, with the inclusion of linezolid and bedaquiline in chemotherapy regimens. Material and methods. A non-randomized, continuous, single-center retrospective study was conducted involving 114 patients who underwent surgery at the National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of Russia between 2018 and 2022. A comparative analysis of the effectiveness of chemotherapy regimens was carried out in patients with localized and extensive tuberkulosis forms. Results. In 41.6% (n=32/77) of patients with tuberculosis and in 18.9% (n=7/37) with fibrous-cavernous tuberculosis, a statistically significantly higher spectrum of МВТ was detected in the study of resection samples compared with inspiratory materials (p=0.03). The inclusion of linezolid and bedaquiline in the chemotherapy regimen in MDR-TB patients led to a reduction in the duration of postoperative treatment by an average of 14.0±1.3 and 11.1±4.5 weeks in limited forms and by 14.8±3.2 and 14.9±3.7 weeks in common forms of ТВ, compared with chemotherapy regimens that do not include these drugs. Conclusion. The addition of novel anti-tuberculosis drugs such as linezolid and bedaquiline to the chemotherapy regimen for patients with multidrug-resistant tuberculosis can reduce the duration of treatment for both localized and extensive forms of the disease.

Keywords: anti-tuberculosis therapy, bedaquiline, drug resistance, linezolid, surgical material, tuberculosis

Bibliography:
1. Mozhokina GN, Samoylova AG, Vasilyeva IA, Russkikh AE. Medications for short-course chemotherapy of drug resistant tuberculosis and their effect on the host. Tuberculosis and Lung Diseases. 2022;100(8):54-64. DOI:10.21292/2075-123 0-2022-100-8-54-64
2. World Health Organization. Global tuberculosis report 2024. Geneva: WHO; 2024. Licence: CC BY-NC-SA3.0 IGO.
3. Vasilyeva IA, Samoylova AG, Zimina VN, et al. Chemotherapy for tuberculosis in Russia — the story continues. Tuberculosis and Lung Diseases. 2023;101(2):8-12. DOI: 10.58838/2 075-1230-2023-101-2-8-12
4. Некрасов E.B., Трусов B.H., Токаев Т. К. Роль лабораторных методов исследования операционного материала в определении режимов противотуберкулезной терапии. Туберкулез и социально значимые заболевания. 2019;2:40-5.
5. Borodulina ЕА, Rogozhkin PV, Olefirov AS. Drug resistance of Mycobacterium tuberculosis obtained from surgical material in patients with pulmonary tuberculosis. Medical Alliance. 2021;9(1):6-10.
6. Uraksina М, Rogozhkin Р, Eremenko Е. Determination of drug resistance of Mycobacterium tuberculosis in the operating material. Bull Acad Sci Mold Med Sci. 2021;69(1). DOI:10.52692/1857-0011.2021.1-69.09
7. Konovalova NM, Odinets VS, Vasilenko Tl, Zadremaylova ТА. Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple and extensive drug resistance. Tuberculosis and Lung Diseases. 2017;95(12):49-53. DOI:10.21292/2075-1230-2017-95-12-49-53
8. Panova LV, Ovsyankina ES, Khiteva AY, Krushinskaya EA. Experience of using two courses of bedaquiline in the adolescent with extensive drug resistant fibrous cavernous tuberculosis. Tuberculosis and Lung Diseases. 2019;97(7):56-60. DOI:10.21292/2075-1230-2019-97-7-56-60
9. Nechaeva OB. Socially important infectious diseases posing a biological threat to the population of Russia. Tuberculosis and Lung Diseases. 2019;97(11 ):7—17. DOI: 10.21292/2075-1230-2019-97-11-7-17
10. Ruzanov DY, Skryagina ЕМ, Bujnevich IV New schemes and new drugs in the treatment of tuberculosis: Are we keeping pace? Clinical Microbiology and Antimicrobial Chemotherapy. 2021;23(1):27-42. DOI:10.36488/cmac.2021.1.27-42
11. Shishlova AS. Organization of treatment of patients with drug-resistant forms of tuberculosis. Mezdunarodnyj naucno-issledovatel'skij zurnal = International Research Journal. 2024;9 (147):1-8.
12. Malik AM, Stancheva MV Effectiveness of treatment of patients with multidrug-resistant tuberculosis depending on the therapeutic regimen. Smol Med Almanac. 2016;4. URL: https:// cyberleninka.ru/article/n/effektivnost-lecheniya-patsientov-s-tuberkulezom-s-mnozhestvennoy-lekarstvennoy-ustoychivostyu-vozbuditelya-v-zavisimosti-ot/viewer (20 Apr 2025).
13. Vinokurova МК, Yakovleva LP, Kondakov SN, Petukhova NYu. The effectiveness of treatment and follow-up of newly diagnosed patients with multidrug-resistant pulmonary tuberculosis. Fundamental Research. 2013;7(2):286-90.
14. Belousova KV, Kravchenko MA, Berdnikov RB. Comparative analysis of clinically significant biological properties of Mycobacterium tuberculosis isolated from respiratory material. Fundamental Research. 2014;9(11):2452-5.
15. Belousova KV, Umpeleva TV, Eremeeva Nl, et al. Drug susceptibility and genotype affinity of Mycobacterium tuberculosis isolated from surgical specimens of pulmonary tuberculosis patients. Tuberculosis and Lung Diseases. 2019;97(7):11-7. DOI:10.21292/2075-1230-2019-97-7-11-17
16. Borodulin BE, Borodulina EA, Eremenko EP. Ambulatory Phthisiology: textbook. Moscow: KnoRus, 2022; 418 p.8 17. Sinitsyn MV, Kalinina ЕМ, Belilovsky SE, et al. Tuberculosis treatment in modern conditions. Therapeutic Archive (TerArkh). 2020;92 (8):86-94. DOI:10.26442/00403660.2020.08.000762
18. Skryagina ЕМ. The effectiveness of tuberculosis treatment in patients with different periods of outpatient and in-patient treatment. Med Zh. 2022; 1(79): 106-13.
19. Zellweger J-P Modern possibilities of treating tuberculosis with multidrug-resistant mycobacteria. Bulletin of the International Scientific Surgical Association (BISSA). 2017;6(4):5-12.
20. Ivanova DA, Borisov SE, Rodina OV, et al. Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019. Tuberculosis and Lung Diseases. 2020;98(1):5-15. DOI:10.21292/2075-1230-2020-98-1-5-15

AttachmentSize
2025_02_187-193.pdf365.56 KB
All articles of the authors: Sinitsyn M.V., Suleimanov S.Z.

No votes yet